Australia paves the way for a more humane approach to therapeutic cannabis
Research shows that the majority of Australians support the integration of therapeutic cannabis into the healthcare system
Published on 11/27/2025
Australia sees growing confidence in medical cannabis as part of daily care | Reproduction AI
Amid an increasingly open debate about well-being and quality of life, Australia shows signs that the population already sees therapeutic cannabis as a natural part of the future of health.
According to the Cáñamo website, a new survey shows that popular support is rapidly growing and is helping to drive important changes in the country.
The research indicates that 64% of Australians believe that medical cannabis should be fully integrated into the traditional healthcare system. Moreover, 66% of respondents claim to trust that their doctors are prepared to use the plant in specific treatments, reinforcing the perception that the topic has already moved beyond the taboo phase and is advancing into the realm of responsible clinical practice.
Another point worth noting is the role of telemedicine. Still according to the Cáñamo website, 94% of the population sees remote consultations as an essential gateway to expanding access to treatments, especially in regions far from major centers.
For 75% of participants, teleconsultation facilitates access to healthcare as a whole, and about a third believe that this type of service will be predominant in the coming years.
A new perspective on care
According to Nicole Le Maistre, CEO of Leafio, the data shows an important cultural shift. She emphasizes that patients are seeking more flexibility in consultations, home delivery of medications, and autonomy over their treatments, factors that, according to the website, have strengthened the conversation about regulating cannabis safely and transparently.
Regulatory debates are ongoing
Despite the optimism, the study also raises concerns among healthcare professionals. Experts warn of risks from models with excessive prescriptions and advocate for more balance between access and clinical rigor. In this scenario, the Australian government is already considering new regulatory revisions, seeking to adapt the rules to the market reality and the needs of patients.
With information from Cañamo.Net.
